Next-level medicine with ease.

Next-level medicine
with ease.

We are a clinical-stage biopharmaceutical company unlocking difficult-to-produce biologics based on a transformative manufacturing platform.

Company

Developing unique medicines for patients.

Current Pipeline

Two innovative therapies for orphan diseases.

Technology

Smart biologics for a range of indications enabled by moss.

Product
Spotlight

A unique opportunity in complement
disorders: Factor H (CPV-104)

Team

Eleva’s team combines decades of scientific and industry experience. We relentlessly pursue those therapeutic opportunities, where our technology and expertise can make a key difference and deliver next-level medicines to patients.

  • Björn Cochlovius, Ph.D., Assoc. Prof.
    Chief Executive Officer & Managing Director
  • Dr. Andreas Schaaf, Ph.D.
    Chief Scientific Officer & Managing Director
  • Jana Gross, MBA
    Director Business Development
  • Dr. Paulina Dabrowska-Schlepp
    Director Analytical Science & Technology
Partner
Spotlight

Eleva boosts capacity for platform and pipeline with 3PBIOVIAN alliance

News

Eleva will be at the forefront of unlocking unique biological therapies across several indications with an equally unique expression platform. Stay up to date on our progress to learn more about how Eleva can change patient’s lives and help forge therapies that might otherwise be neglected.

  • May 28, 2025

    Webinar Five 
    ...focuses on Age-related Macular Degeneration (AMD), a chronic retinal disease that primarily affects older adults and represents one of the leading causes of vision loss in aging populations.
News

Stay in the loop and subscribe Eleva’s newsletter

Career

Eleva offers a workplace that is focused on a valuable goal – bringing unique therapies to patients in need.

Next Page

Company